These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 36052502)

  • 1. Why ARNT Prostate Tumors Responding to Enzalutamide?
    Zhang M; Moreno-Rodriguez T; Quigley DA
    Cancer Discov; 2022 Sep; 12(9):2017-2019. PubMed ID: 36052502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
    Linder S; Hoogstraat M; Stelloo S; Eickhoff N; Schuurman K; de Barros H; Alkemade M; Bekers EM; Severson TM; Sanders J; Huang CF; Morova T; Altintas UB; Hoekman L; Kim Y; Baca SC; Sjöström M; Zaalberg A; Hintzen DC; de Jong J; Kluin RJC; de Rink I; Giambartolomei C; Seo JH; Pasaniuc B; Altelaar M; Medema RH; Feng FY; Zoubeidi A; Freedman ML; Wessels LFA; Butler LM; Lack NA; van der Poel H; Bergman AM; Zwart W
    Cancer Discov; 2022 Sep; 12(9):2074-2097. PubMed ID: 35754340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature.
    Vellky JE; Kirkpatrick BJ; Gutgesell LC; Morales M; Brown RM; Wu Y; Maienschein-Cline M; Notardonato LD; Weinfeld MS; Nguyen RH; Brister E; Sverdlov M; Liu L; Xu Z; Kregel S; Nonn L; Vander Griend DJ; Reizine NM
    Clin Cancer Res; 2024 Apr; 30(8):1530-1543. PubMed ID: 38306015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
    Alumkal JJ; Sun D; Lu E; Beer TM; Thomas GV; Latour E; Aggarwal R; Cetnar J; Ryan CJ; Tabatabaei S; Bailey S; Turina CB; Quigley DA; Guan X; Foye A; Youngren JF; Urrutia J; Huang J; Weinstein AS; Friedl V; Rettig M; Reiter RE; Spratt DE; Gleave M; Evans CP; Stuart JM; Chen Y; Feng FY; Small EJ; Witte ON; Xia Z
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12315-12323. PubMed ID: 32424106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
    Centenera MM; Selth LA; Ebrahimie E; Butler LM; Tilley WD
    Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29530945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
    Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
    Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
    Grist E; de Bono JS; Attard G
    J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.
    Hwang JH; Seo JH; Beshiri ML; Wankowicz S; Liu D; Cheung A; Li J; Qiu X; Hong AL; Botta G; Golumb L; Richter C; So J; Sandoval GJ; Giacomelli AO; Ly SH; Han C; Dai C; Pakula H; Sheahan A; Piccioni F; Gjoerup O; Loda M; Sowalsky AG; Ellis L; Long H; Root DE; Kelly K; Van Allen EM; Freedman ML; Choudhury AD; Hahn WC
    Cell Rep; 2019 Nov; 29(8):2355-2370.e6. PubMed ID: 31747605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
    Lim AC; Attard G
    Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
    Westbrook TC; Guan X; Rodansky E; Flores D; Liu CJ; Udager AM; Patel RA; Haffner MC; Hu YM; Sun D; Beer TM; Foye A; Aggarwal R; Quigley DA; Youngren JF; Ryan CJ; Gleave M; Wang Y; Huang J; Coleman I; Morrissey C; Nelson PS; Evans CP; Lara P; Reiter RE; Witte O; Rettig M; Wong CK; Weinstein AS; Uzunangelov V; Stuart JM; Thomas GV; Feng FY; Small EJ; Yates JA; Xia Z; Alumkal JJ
    Nat Commun; 2022 Sep; 13(1):5345. PubMed ID: 36109521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Long Noncoding RNA
    Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
    Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.
    Ning S; Liu C; Lou W; Yang JC; Lombard AP; D'Abronzo LS; Batra N; Yu AM; Leslie AR; Sharifi M; Evans CP; Gao AC
    Mol Cancer Ther; 2022 Oct; 21(10):1594-1607. PubMed ID: 35930737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.
    Rodríguez Y; Unno K; Truica MI; Chalmers ZR; Yoo YA; Vatapalli R; Sagar V; Yu J; Lysy B; Hussain M; Han H; Abdulkadir SA
    Cancer Res; 2022 Jun; 82(11):2110-2123. PubMed ID: 35405009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
    Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
    J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
    Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
    Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging mechanisms of enzalutamide resistance in prostate cancer.
    Claessens F; Helsen C; Prekovic S; Van den Broeck T; Spans L; Van Poppel H; Joniau S
    Nat Rev Urol; 2014 Dec; 11(12):712-6. PubMed ID: 25224448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.